Risk prediction models that are based on medical history or the results of tests are becoming common in the cancer literature and are used to provide additional information to those who are involved in making treatment decisions on the basis of estimated risk.

In this commentary, Stuart G. Baker, ScD, of the National Cancer Institute in Bethesda, Md., elaborates on the relative utility curve as a method for evaluating...

In order to view the entire article, please read your options to the right